Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.
Bonfanti, P., Gulisano, C., Ricci, E., Timillero, L., Valsecchi, L., Carradori, S., et al. (2003). Risk factors for lipodystrophy in the CISAI cohort. BIOMÉDECINE & PHARMACOTHÉRAPIE, 57(9), 422-427 [10.1016/j.biopha.2003.06.002].
Risk factors for lipodystrophy in the CISAI cohort
Bonfanti P.
;
2003
Abstract
Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
risk factors fol lipo.pdf
Solo gestori archivio
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Dimensione
134.04 kB
Formato
Adobe PDF
|
134.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.